Spectrum Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Henderson NV United States (2002)
Status: Acquired by Repligen Corporation (2017)

Organization Overview

First Clinical Trial
2002
NCT00004202
First Marketed Drug
2002
fluorouracil (efudex)
First NDA Approval
2008
levoleucovorin (fusilev)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Neos Tx | NeoTherapeutics | Spectrum Pharmaceuticals, Inc | Spectrum Pharmaceuticals, Inc. | SPECTRUM PHARMS

Active Ingredients

Marketed Drugs (6)

belinostat (beleodaq) (2014 NDA)

eflapegrastim (Rolvedon) (2022)

fluorouracil (efudex) (1962)

ibritumomab tiuxetan (Zevalin) (2009)

levoleucovorin (fusilev) (2008 NDA)

melphalan (alkeran) (2016)

Drugs in Phase 3 Trials (20)

apaziquone (7 trials)

carboplatin (paraplatin) (4 trials)

cisplatin (platinol) (2 trials)

cyclophosphamide (cytoxan) (7 trials)

docetaxel (taxotere) (6 trials)

efaproxiral (4 trials)

eflapegrastim (Rolvedon) (5 trials)

Filgrastim (neupogen) (6 trials)

gemcitabine (gemzar) (2 trials)

ibritumomab tiuxetan (Zevalin) (9 trials)

methylphenidate (ritalin) (1 trial)

oxygen (1 trial)

ozarelix (3 trials)

paclitaxel (taxol) (4 trials)

poziotinib (11 trials)

pralatrexate (folotyn) (15 trials)

prednisone (meticorten) (3 trials)

rituximab (rituxan) (10 trials)

vincristine (oncovin) (15 trials)

vinorelbine (navelbine) (2 trials)

Drugs in Phase 2 Trials (42)

Key: Spectrum Pharmaceuticals (41) Acquired (1)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (2 trials)

autologous hematopoietic stem cells (2 trials)

belinostat (beleodaq) (12 trials)

bendamustine (treanda) (3 trials)

bortezomib (velcade) (2 trials)

clofarabine (clolar) (1 trial)

cyanocobalamin (berocca) (8 trials)

cyclosporine (sandimmune) (1 trial)

cytarabine (cytosar-u) (3 trials)

doxorubicin (Doxil) (3 trials)

elsamitrucin (2 trials)

erlotinib (tarceva) (1 trial)

etoposide (vepesid) (2 trials)

fludarabine (fludara) (1 trial)

fludeoxyglucose f-18 (1 trial)

folic acid (8 trials)

goserelin (zoladex) (1 trial)

ign002 (2 trials)

imatinib (gleevec) (1 trial)

leteprinim (1 trial)

leucovorin (1 trial)

lucanthone (2 trials)

melphalan (alkeran) (5 trials)

mercaptopurine (purinethol) (1 trial)

mesna (mesnex) (1 trial)

methylprednisolone (medrol) (1 trial)

mitoxantrone (novantrone) (1 trial)

motexafin gadolinium (1 trial)

mycophenolate (CellCept) (2 trials)

naltrexone (revia) (3 trials)

nelarabine (arranon) (1 trial)

palifermin (Kepivance) (1 trial)

panobinostat (farydak) (1 trial)

pegaspargase (oncaspar) (1 trial)

sargramostim (leukine) (2 trials)

sovateltide (3 trials)

stem cells (1 trial)

tacrolimus (prograf) (1 trial)

talotrexin (3 trials)

temozolomide (temodar) (2 trials)

urea (4 trials)

Drugs in Phase 1 Trials (13)

bexarotene (targretin) (1 trial)

ciprofloxacin (cipro) (1 trial)

fluconazole (diflucan) (1 trial)

Ginsenoside rh-1 (1 trial)

itraconazole (sporanox) (1 trial)

levoleucovorin (fusilev) (2 trials)

menadiol (synkavite) (1 trial)

paroxetine (paxil) (1 trial)

phenytoin (mesantoin) (1 trial)

renazorb (1 trial)

topotecan (hycamtin) (1 trial)

trastuzumab emtansine (kadcyla) (1 trial)

warfarin (coumadin) (1 trial)

Indications

Approved Indications


 

Colorectal Neoplasms

Lymphoma, T-Cell, Peripheral

Osteosarcoma

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 1)

Adenocarcinoma (Phase 2)

Amyloidosis (Phase 2)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Biliary Tract Neoplasms (Phase 2)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 1)

Carcinoma, Transitional Cell (Phase 2)

Esophageal Neoplasms (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Exanthema (Phase 1)

Glioblastoma (Phase 2)

Hodgkin Disease (Phase 2)

Hyperkinesis (Phase 3)

Hyperplasia (Phase 2)

Hypertrophy (Phase 3)

Immunoblastic Lymphadenopathy (Phase 2)

Immunoglobulin Light-chain Amyloidosis (Phase 2)

Leukemia (Phase 3)

Leukemia, B-Cell (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, T-Cell (Phase 2)

Lower Urinary Tract Symptoms (Phase 3)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, B-Cell, Marginal Zone (Phase 1)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Lymphoma, T-Cell (Phase 3)

Lymphoma, T-Cell, Cutaneous (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 3)

Melanoma (Phase 2)

Mucositis (Phase 2)

Multiple Myeloma (Phase 2)

Mycoses (Phase 1)

Mycosis Fungoides (Phase 1)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Neoplasms, Second Primary (Phase 3)

Neoplasms, Unknown Primary (Phase 2)

Nervous System Diseases (Phase 2)

Neuroblastoma (Phase 2)

Neutropenia (Phase 3)

Ovarian Neoplasms (Phase 1)

Peripheral Nervous System Diseases (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Prostatic Hyperplasia (Phase 3)

Prostatic Neoplasms (Phase 2)

Renal Insufficiency (Phase 1)

Sarcoma (Phase 2)

Sezary Syndrome (Phase 1)

Small Cell Lung Carcinoma (Phase 1)

Urinary Bladder Neoplasms (Phase 3)

Uveal Neoplasms (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Wilms Tumor (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 103
  • # of Trial APIs: 75